SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

Share Price is delayed by 15 minutes
Get Live Data
17.00    0.00 (0.00%)
Bid:
16.00
Ask:
18.00
Spread: 2.00 (12.50%)
Market Cap: £12.86m
FIPP Live PriceLast checked at - London Stock Exchange

Intraday Frontier Ip Share Chart

New portfolio company

2 Mar 2015 07:00

RNS Number : 1646G
Frontier IP Group plc
02 March 2015
 



 

 

AIM: FIPP

 

Frontier IP Group plc

("Frontier IP")

 

New Portfolio Company - Cambridge Sensor Technologies Ltd

Frontier IP, which specialises in the commercialisation of intellectual property, is pleased to announce that it has received a stake in Cambridge Sensor Technologies Limited ("CST"), a company formed to exploit the technology developed by Dr. Mark Williamson, a lecturer and researcher at the Department of Chemical Engineering and Biotechnology at the University of Cambridge. Frontier IP has entered into an agreement with CST in which it has agreed to provide advisory and business development services in return for a 40% equity stake in the new company.

Dr. Williamson develops heating system, sensors and control strategies for industrial processes in which the composition of the processing atmosphere is important. The benefits of the technology include reduction in energy consumption and improvement/optimisation of the quality and consistency of the manufactured goods. A program of industrial trials is already underway, in collaboration with major multinational companies in the food and speciality chemicals sectors.

Neil Crabb, Chief Executive of Frontier IP, said,

"We are looking forward to working with Dr. Williamson on this new opportunity. Frontier IP brings experience in commercialising IP and relationships with key players in relevant markets. Dr. Williamson's industry-focused approach combined with our support can help accelerate the commercialisation for this exciting technology."

Enquiries

 

Frontier IP Group Plc

0131 240 1251

Neil Crabb, Chief Executive

Company website: www.frontierip.co.uk

 

Cantor Fitzgerald Europe

(Nominated Adviser and Joint Broker)

020 7894 7000

Mark Percy / Catherine Leftley, Corporate Finance

David Banks, Corporate Broking

Peterhouse Corporate Finance Limited (Joint Broker)

020 7469 0935

Lucy Williams

KTZ Communications

020 3178 6378

Katie Tzouliadis / Deborah Walter

 

 

Notes to Editor:

 

Frontier IP Group plc www.frontierip.co.uk 

Frontier IP specialises in assisting universities, research institutions and companies in the commercialisation and exploitation of their Intellectual Property.

Department of Chemical Engineering and Biotechnology, University of Cambridge

The Department of Chemical Engineering and Biotechnology at the University of Cambridge is a leading global research department. It is ranked top for research in its discipline in the UK, best in the world outside the US and 4th in the world including the US (HEFCE REF 2014 and QS World University Rankings by Subject 2014). Working effectively with industry is a core strength of the Department, as is progressing novel technologies through spinout companies and licensing agreements to ultimate launch of marketed products.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCPGUMUPUPAGRM
Date   Source Headline
26th May 20267:00 amRNS-RPortfolio news: Dekiln strategic partnership
5th May 20267:00 amRNSAppointment of Chief Financial Officer
16th Apr 20264:07 pmRNSHolding(s) in Company
15th Apr 20267:00 amRNSPortfolio News: 2D Photonics subsidiary grant
13th Apr 20262:35 pmRNSHolding(s) in Company
10th Apr 202610:30 amRNSUpdate re Investee Company
8th Apr 20267:00 amRNS-RPortfolio news – Fieldwork Robotics £3M fundraise
31st Mar 20265:18 pmRNSHolding(s) in Company
30th Mar 20267:00 amRNSUnaudited Half Year Results
23rd Mar 20267:00 amRNS-RAlusid reaches milestone in European roll out
28th Jan 20264:28 pmRNSHolding(s) in Company
19th Jan 20267:00 amRNS-RPortfolio news - Strong results for TVG vaccine
12th Jan 202610:30 amRNSHolding(s) in Company
31st Dec 20251:00 pmRNSTotal Voting Rights
31st Dec 20251:00 pmRNSTotal Voting Rights
31st Dec 202512:30 pmRNSResult of AGM
31st Dec 202512:30 pmRNSResult of AGM
29th Dec 20252:37 pmRNSHolding(s) in Company
29th Dec 20252:37 pmRNSHolding(s) in Company
24th Dec 20259:52 amRNSHolding(s) in Company
24th Dec 20259:52 amRNSHolding(s) in Company
24th Dec 20257:00 amRNSHolding(s) in Company
23rd Dec 20252:17 pmRNSDirectors' Shareholdings
23rd Dec 20252:17 pmRNSDirectors’ Shareholdings
22nd Dec 20253:48 pmRNSResult of Retail Offer
22nd Dec 20253:48 pmRNSResult of Retail Offer
18th Dec 20259:15 amRNS-RDekiln benefits from £3 million funding
17th Dec 202511:54 amRNSResult of Placing and Subscription
17th Dec 20257:01 amRNSRetail Offer
17th Dec 20257:00 amRNSProposed Placing and Subscription to raise £870k
15th Dec 20257:00 amRNS-RPortfolio news- Alusid £500k pre-IPO funding round
10th Dec 20254:56 pmRNSHolding(s) in Company
9th Dec 20257:00 amRNSPosting of Annual Report & Notice of AGM
8th Dec 20257:00 amRNSFinal results for the year ended 30 June 2025
2nd Dec 20257:00 amRNS-RAlusid signs Swedish distribution agreement
6th Nov 20257:00 amRNSBord Change
3rd Nov 20257:00 amRNS-RTVG demonstrates success in animal trials
20th Oct 20257:00 amRNS-RAmprologix raises £740,000 in Pre-Series A round
25th Sep 20257:00 amRNSBoard Changes
24th Sep 20255:12 pmRNSHolding(s) in Company
13th Jun 20257:00 amRNSStrategic partnership for Cambridge innovation hub
10th Jun 20257:00 amRNS-RAlusid signs international distribution agreement
6th May 20257:00 amRNS-RTVG's vaccine candidate enters animal trials
16th Apr 20257:00 amRNS-RSyva signs option to license agreement with TVG
2nd Apr 20254:47 pmRNSDirector/PDMR Shareholding
31st Mar 20251:02 pmRNSDirector/PDMR Shareholding
26th Mar 20257:00 amRNSUnaudited Half Year Results
24th Mar 20257:00 amRNSCamGraphIC secures €25 million in Series A funding
18th Mar 20257:00 amRNS-RPulsiv wins PSMA’s Global Energy Efficiency Award
25th Feb 20257:00 amRNS-RGraphEnergyTech collaboration & Innovate UK grant

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.